So with those organizations, what are you hearing from them about this project, about this operation, and how does it maybe match up to what sponsors are talking about on their side as well, sitting in that place where you're bringing these two constituency groups together?

Yeah, it's an interesting question.

On the site side, I think there's a lot of interest and a lot of excitement around what is coming.

The document that was released for Trial Blazer itself points very specifically to academic centers, which I think are important to include in operations where we're trying to figure out how to better speed trials.

But it doesn't address the full site network, so I think there's some revisions coming in trying to prompt the agency to think about that if we want to be successful at changing how trials get done, we also have to look at where they're actually occurring and changing that dynamic as well.

So most of my site constituents are waiting with bated breath to see what's gonna happen because this initiative, combined with the RFI you heard about earlier this year around how to optimize for phase one trials using AI and things like that, are pointing to this fact that the agency is looking for ways to make a digital data transfer easier because they know that's how we're gonna speed up trials is by getting rid of the paper and the people that have to manage that data, not getting rid of them, but better optimizing them to do cooler things like actually see patients.

So I think sites are waiting to see how that's gonna play out for them.

Where and how can sites absorb the volume if conditions really showed up tomorrow, if things started to shift for us?